These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32060406)

  • 1. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
    Mason MJ; Schinke C; Eng CLP; Towfic F; Gruber F; Dervan A; White BS; Pratapa A; Guan Y; Chen H; Cui Y; Li B; Yu T; Chaibub Neto E; Mavrommatis K; Ortiz M; Lyzogubov V; Bisht K; Dai HY; Schmitz F; Flynt E; Dan Rozelle ; Danziger SA; Ratushny A; ; Dalton WS; Goldschmidt H; Avet-Loiseau H; Samur M; Hayete B; Sonneveld P; Shain KH; Munshi N; Auclair D; Hose D; Morgan G; Trotter M; Bassett D; Goke J; Walker BA; Thakurta A; Guinney J
    Leukemia; 2020 Jul; 34(7):1866-1874. PubMed ID: 32060406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
    Li Y; Gong J; Zhang L
    J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
    Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
    Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
    Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
    J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
    Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PHF19 inhibition as a therapeutic target in multiple myeloma.
    Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
    Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
    Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
    Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma.
    Yi W; Dziadowicz SA; Mangano RS; Wang L; McBee J; Frisch SM; Hazlehurst LA; Adjeroh DA; Hu G
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
    Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
    Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
    Jiang H; Gao W; Sze DM; Xiong H; Hou J
    Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
    Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
    Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
    Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
    Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
    Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
    Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in gene expression profiles in multiple myeloma cells after knocking-down SNF5, a core subunit of SWI/SNF complex].
    Xie Y; Xu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 May; 33(5):667-71. PubMed ID: 23688984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
    Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
    Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
    Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
    Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
    Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
    Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
    Dupéré-Richer D; Licht JD
    Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.